NAC

N-acetylcysteine (NAC) is the acetylated form of L-cysteine, the rate-limiting amino acid substrate for hepatic glutathione (GSH) synthesis. The acetyl group improves oral bioavailability and protects the cysteine moiety from oxidation in the GI tract. NAC is the standard pharmacological antidote in acetaminophen overdose — the use case where it has the strongest direct clinical evidence.

Mechanism — glutathione precursor:

Glutathione is the dominant hepatic phase-II conjugation cofactor used to detoxify drugs and reactive metabolites. The pathway: hepatocyte takes up xenobiotic → CYP450-mediated phase I oxidation produces reactive intermediate → glutathione-S-transferase conjugates the reactive species with GSH → conjugate is excreted biliarily or renally. The pathway depletes GSH faster than dietary cysteine can replenish during high-load exposure.

NAC restores the precursor supply. Within 4–6 hours of oral dosing, hepatic GSH concentration rises measurably; chronic dosing maintains elevated GSH at steady-state.

Clinical evidence base:

– Acetaminophen overdose: Smilkstein et al. 1988, NEJM — the foundational NAC study establishing it as standard of care in paracetamol toxicity. NAC at 140 mg/kg loading + 70 mg/kg q4h × 17 doses prevents hepatic failure in patients presenting within 8 hours of overdose.
– Chronic obstructive pulmonary disease: modest mucolytic and antioxidant effects; mixed evidence base.
– AAS hepatoprotection: mechanism-extrapolated from acetaminophen data. Both involve glutathione depletion in CYP-mediated phase-I metabolism. Direct AAS-specific clinical trial data is limited; user-reported bloodwork shows smaller ALT elevation patterns versus unsupplemented controls, supporting the mechanistic case.
– Psychiatric applications: emerging evidence for NAC in OCD, schizophrenia, and trichotillomania at higher doses (1800–2400 mg/day) via glutamatergic modulation.

Dosing protocol for AAS hepatoprotection:

– Standard: 1200 mg/day, split 600 mg AM and 600 mg PM
– Higher load (severe oral protocols): 1800 mg/day in 3 divided doses
– Pre-loading: start with the rest of the hepatoprotective stack 7 days before first oral dose
– Maintenance: continue 2 weeks past last oral dose

Tolerability:

– Slight sulfurous taste in liquid form (the cysteine moiety smells of egg). Encapsulated NAC eliminates the issue.
– Rare GI upset at higher doses; manageable with food.
– Unsubstantiated concerns about NAC interfering with training adaptation through antioxidant effects — the evidence in athletes is modest and the dose-response curve does not support meaningful interference at hepatoprotective dosing.
– Generally regarded as safe at hepatoprotective doses; long-term clinical use in cystic fibrosis populations supports the safety profile.

Stack synergy with TUDCA:

NAC and TUDCA address different mechanisms of hepatic stress — NAC supports phase II detoxification capacity; TUDCA addresses bile-acid pool toxicity. The combination produces additive rather than redundant protection. Standard hepatoprotective stack for 17α-alkylated oral cycles: TUDCA 500 mg/day + NAC 1200 mg/day, started 7 days pre-cycle, continued 2 weeks post-cycle.